PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 142 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,025,503 | -25.3% | 61,481 | +23.8% | 0.00% | -25.0% |
| Q2 2023 | $1,372,079 | +64.9% | 49,677 | +37.3% | 0.00% | +100.0% |
| Q1 2023 | $831,887 | -32.0% | 36,169 | -67.8% | 0.00% | -50.0% |
| Q4 2022 | $1,224,047 | +241.9% | 112,195 | +163.9% | 0.00% | +300.0% |
| Q3 2022 | $358,000 | +2.0% | 42,513 | -4.1% | 0.00% | 0.0% |
| Q2 2022 | $351,000 | -72.3% | 44,333 | -17.1% | 0.00% | -66.7% |
| Q1 2022 | $1,267,000 | -42.6% | 53,500 | -17.2% | 0.00% | -25.0% |
| Q4 2021 | $2,209,000 | +75.0% | 64,600 | -9.3% | 0.00% | +33.3% |
| Q3 2021 | $1,262,000 | -54.4% | 71,200 | +15.6% | 0.00% | -50.0% |
| Q2 2021 | $2,765,000 | +98.8% | 61,600 | +14.7% | 0.01% | +100.0% |
| Q1 2021 | $1,391,000 | +24.5% | 53,700 | -3.1% | 0.00% | 0.0% |
| Q4 2020 | $1,117,000 | +8.0% | 55,400 | +4.7% | 0.00% | 0.0% |
| Q3 2020 | $1,034,000 | +542.2% | 52,900 | +132.0% | 0.00% | – |
| Q4 2019 | $161,000 | -41.2% | 22,800 | 0.0% | 0.00% | -100.0% |
| Q3 2019 | $274,000 | – | 22,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $56,331,209 | 18.32% |
| Kynam Capital Management, LP | 1,375,000 | $31,625,000 | 4.08% |
| BVF INC/IL | 3,775,900 | $86,845,700 | 3.18% |
| Cormorant Asset Management, LP | 1,700,000 | $39,100 | 2.58% |
| RTW INVESTMENTS, LP | 4,600,799 | $105,818,377 | 2.20% |
| Ghost Tree Capital, LLC | 225,000 | $5,175,000 | 1.53% |
| 683 Capital Management, LLC | 791,000 | $18,193,000 | 1.36% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 105,486 | $2,426,178 | 1.00% |